You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 139 No. 10, October 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Correspondence
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Medical Practice
 •Medical Ethics
 •Dermatology
 •Randomized Controlled Trial
 •Dermatologic Disorders, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

COMMENTS AND OPINIONS
1% Pimecrolimus Cream for Atopic Dermatitis

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In an article that appeared in the "Evidence-Based Dermatology: Research Commentary" section of the ARCHIVES, Dr Williams1 raised several questions concerning an article that reported the results of a study on 1% pimecrolimus cream for the treatment of mild and moderate atopic dermatitis in children and adolescents.2 As the authors of that article, we would like to respond to Dr Williams' comments, because it is our belief that the efficacy of topical pimecrolimus has been evidentially demonstrated.

Dr Williams asks, "[H]ow well was the study reported? (ie, should we believe the results?) . . . ." The reporting of a study is limited by the scientific publication process, which requires concise summaries of studies, with aggressive editing of text and figures prior to submission and during the journal's editorial process. Some of the details of the study design were not included in the Journal of the American Academy of Dermatology . . . [Full Text of this Article]

Lawrence F. Eichenfield, MD
Children's Hospital and Health Center
Pediatric And Adolescent Dermatology
8010 Frost St, Suite 602
San Diego, CA 92123
(e-mail: leichenfield@ucsd.edu)

Anne W. Lucky, MD; Mark Boguniewicz, MD; Richard G. B. Langley, MD; Robert Cherill; Katharine Marshall
San Diego



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

1% Pimecrolimus Cream for Atopic Dermatitis—Reply
Hywel Williams
Arch Dermatol. 2003;139(10):1370-1371.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.